SCHEMBL5538898

SCHEMBL5538898

[CH2]CN(C)c1cccc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CETP P11597 2/20 0.42
EGFR P00533 2/20 0.42
CSF1R P07333 2/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TP53 P04637 1/20 0.41
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
PNMT P11086 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
GAA P10253 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTR7 P34969 1/20 0.39
RORC P51449 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541971 0.86 HTR7 (0.42) CETPEGFRCSF1RTSHRMAPK1
SCHEMBL4617153 0.84 CETP (0.43) CETPEGFRCSF1RTSHRMAPK1
SCHEMBL5543914 0.81 TACR1 (0.43) ALDH1A1IDO1CES2
SCHEMBL19265466 0.81 HTR7 (0.43) CETPTSHRMAPK1HTR2AHTR2C
SCHEMBL30901511 0.79 TSHR (0.48) CETPEGFRCSF1RTSHRMAPK1
SCHEMBL171829 0.79 TSHR (0.48) CETPEGFRCSF1RTSHRMAPK1
SCHEMBL2099195 0.77 KIF11 (0.43) TSHRSLC6A2SLC6A4SLC6A3TAAR1
Hydrochloric Acid SCHEMBL2190046 0.77 TSHR (0.47) CETPEGFRCSF1RTSHRMAPK1
SCHEMBL20322772 0.77 UTS2R (0.48) MEN1KMT2ATP53ALDH1A1RORC
SCHEMBL10426059 0.76 TP53 (0.46) TP53ALDH1A1RORCCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CETP 4769/4885EGFR 3049/4885CSF1R 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.